Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors.

Anthony W TolcherMichael GordonKathleen M MahoneyAnna SetoMarianna ZavodovskayaChia-Hsiang HsuehShuyan ZhaiThomas TarnowskiJuliane M JürgensmeierSusanna StinsonAhmed A OthmanTianling ChenJames Strauss

Published in: Journal for immunotherapy of cancer (2023)

Dalutrafusp alfa doses up to 45 mg/kg Q2W were well tolerated in patients with advanced solid tumors. Additional evaluation of dalutrafusp alfa could further elucidate the clinical utility of targeting CD73-adenosine and TGF-β pathways in oncology.

Keyphrases

replacement therapy
transforming growth factor
endothelial cells
palliative care
nk cells
induced pluripotent stem cells
cancer therapy
epithelial mesenchymal transition
drug delivery
pluripotent stem cells
metal organic framework